@DrToddLee@ABsteward@DrEmilyMcD Well done for including ampicillin monotherapy. I suspect the outcome is going to be that there is no need for combination therapy.
@ABsteward The first should not constitute a surprising finding, neither the second, as P. aeruginosa can rather easily develop resistance to any antibiotic during therapy
@Zaydovudine@ABsteward But we should be careful about what we extrapolate from clinical trials and do not necessarily disregard well-established in vitro and PK/PD data.
@Zaydovudine@ABsteward the ZEPHyR Trial, where patients were enrolled and began receiving the study drugs based on clinical suspicion alone. Of course, you would need to randomise much more to select those with the infection of interest.
@Zaydovudine@ABsteward I’m afraid the SNAP trial did not answer the question about the preferred empirical treatment for Staph aureus bacteraemia. The initial ~72h of a bacteraemia is the most critical period.
Same for all other antibiotic treatment trials - the only exception to my knowledge being
@BradSpellberg Blood levels of moxifloxacin are reduced with concomitant rifampicin, but may still be adequate to sterilise a deep-seated focus of infection
https://t.co/YuNuxyZIg1
@BradSpellberg@ABsteward Another explanation could be that using procalcitonin in ED could have helped in giving the antibiotics to the right patients, i.e., more patients with bacterial infections getting antibiotics and fewer patients of those with viral infections or other conditions
📚A Themed Issue in Honor of Professor Matthew E. Falagas: #Antimicrobial#Resistance and the #Treatment of Complex Infections
😊Edited by Dr. Drosos E. Karageorgopoulos (@DrososKarag) from @OUHospitals
📆Submission Deadline: 16 June 2026
🔗More at: https://t.co/LtfPGWyAHR
Αν εργάζεσαι σε ένα αντικαρκινικό νοσοκομείο, συνειδητοποιείς, μέσω του πόνου τόσων ανθρώπων, τι πραγματικά έχει σημασία στη ζωή. Το άλμα από το Χαλάνδρι στις ΗΠΑ και οι κλειστές πόρτες των ελληνικών ΑΕΙ. https://t.co/iVAWJaVsXX
Our national study found that for every one hour with patients, UK resident doctors spend four hours on admin.
In @bmj_latest today, we break down why this isn’t just an inconvenience, it’s a safety risk.
1) Fragmented EHRs → endless copy-paste + re-entering data
2) Trainees turned into scribes
3) Less training, less confidence, less preparedness
We suggest:
• Reassign admin to allied staff
• Joined-up IT that fits clinical workflows
• Minimum patient-facing time requirement in training
• Clinicians co-designing digital tools
If you work in healthcare: what’s one admin task you’d automate or reassign tomorrow?
👇 Your answers might shape the fix-list.
Thank you to my co-authors @KaranChhatwal_@HamaadAKhan and Professor Stuart D. Rosen, and BMJ editors @Juliet_hd and @jolie__neill.
You can find the link to the full BMJ piece in the comments.
With thanks to @imperialcollege and @bmj_latest
@TheodoreLytras Και αυτό είναι παρεμφερές https://t.co/99VylNhI76.
Αν έβλεπε κανείς τι διαδικασίες ακολουθούνται για μια μετάγγιση αίματος στο NHS, θα τους θεωρούσε υ��τερικούς.
Αλλά έχουν προκύψει από μακρές διαδικασίες, προπάντων από την αναφορά και ανάλυση των serious incidents & never events
The abrupt terminations of more than 1,000 employees, including new Epidemic Intelligence Officers, across CDC are deeply disturbing. For more than 70 years, EIS officers have served on America’s front line as its disease detectives, ready at a moment’s notice to respond to emerging outbreaks.
Five years ago on 31 December 2019, WHO’s Country Office in #China picked up a media statement by the Wuhan Municipal Health Commission from their website on cases of ‘viral pneumonia’ in Wuhan, China.
In the weeks, months, and years that unfolded after that, #COVID19 came to shape our lives and our world.
At WHO, we went to work immediately as the new year dawned. WHO employees activated emergency systems on 1 January 2020, and informed the world on 4 January.
By 9-12 January, WHO had published its first set of comprehensive guidance for countries, and on 13 January, we brought together partners to publish the blueprint of the first SARS-CoV-2 laboratory test.
All along, we convened experts and ministries of health from around the world, gathered and analysed data, and shared what was reported, what we learned and what it meant for people. Read about WHO’s actions here: https://t.co/ita06DUlq7
As we mark this milestone, let’s take a moment to honour the lives changed and lost, recognize those who are suffering from COVID-19 and #longCOVID, express gratitude to the health workers who sacrificed so much to care for us, and commit to learning from COVID-19 to build a healthier tomorrow.
We continue to call on China to share data and access so we can understand the origins of COVID-19. This is a moral and scientific imperative.
Without transparency, sharing, and cooperation among countries, the world cannot adequately prevent and prepare for future epidemics and pandemics.
Today, as often, we pose this question: “is the world better prepared for the next pandemic than we were for COVID-19?” @DrTedros responds ⬇️